MY189912A - Substituted xanthines and methods of use thereof - Google Patents
Substituted xanthines and methods of use thereofInfo
- Publication number
- MY189912A MY189912A MYPI2015702631A MYPI2015702631A MY189912A MY 189912 A MY189912 A MY 189912A MY PI2015702631 A MYPI2015702631 A MY PI2015702631A MY PI2015702631 A MYPI2015702631 A MY PI2015702631A MY 189912 A MY189912 A MY 189912A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- substituted xanthines
- xanthines
- substituted
- trpc5
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
- 102000003621 TRPC5 Human genes 0.000 abstract 2
- 101150042815 TRPC5 gene Proteins 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789724P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027920 WO2014143799A2 (en) | 2013-03-15 | 2014-03-14 | Substituted xanthines and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY189912A true MY189912A (en) | 2022-03-21 |
Family
ID=50680155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015702631A MY189912A (en) | 2013-03-15 | 2014-03-14 | Substituted xanthines and methods of use thereof |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US9359359B2 (https=) |
| EP (1) | EP2970303B3 (https=) |
| JP (1) | JP6360149B2 (https=) |
| KR (1) | KR102227629B1 (https=) |
| CN (2) | CN107082782B (https=) |
| AU (1) | AU2014228206C1 (https=) |
| CA (1) | CA2899646C (https=) |
| CL (1) | CL2015002738A1 (https=) |
| CY (1) | CY1119042T1 (https=) |
| DK (1) | DK2970303T6 (https=) |
| EA (1) | EA028815B1 (https=) |
| ES (1) | ES2636835T7 (https=) |
| HR (1) | HRP20170840T4 (https=) |
| HU (1) | HUE033528T4 (https=) |
| IL (1) | IL240216B (https=) |
| LT (1) | LT2970303T (https=) |
| MX (1) | MX370372B (https=) |
| MY (1) | MY189912A (https=) |
| NZ (1) | NZ711718A (https=) |
| PE (1) | PE20151779A1 (https=) |
| PH (1) | PH12015502141B1 (https=) |
| PL (1) | PL2970303T6 (https=) |
| PT (1) | PT2970303T (https=) |
| RS (1) | RS56066B2 (https=) |
| SG (1) | SG11201506479TA (https=) |
| SI (1) | SI2970303T1 (https=) |
| TW (1) | TWI609867B (https=) |
| UA (1) | UA117470C2 (https=) |
| UY (1) | UY35488A (https=) |
| WO (1) | WO2014143799A2 (https=) |
| ZA (1) | ZA201505414B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
| CN107082782B (zh) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| GB2553685B (en) | 2015-03-27 | 2020-06-10 | Latvian Inst Organic Synthesis | Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis |
| CA2989161C (en) | 2015-03-27 | 2022-03-01 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use for cancer treatment |
| WO2016159747A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use as calcium ion channel modulators |
| BR112017021386A2 (pt) * | 2015-04-08 | 2018-07-03 | Lewis And Clark Pharmaceuticals, Inc. | carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b. |
| CN107118586A (zh) * | 2016-02-24 | 2017-09-01 | 中国科学技术大学 | 含氮杂环基取代的烯类化合物的用途 |
| GB201702160D0 (en) * | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| CN110573509B (zh) * | 2017-02-28 | 2023-05-26 | 北京生命科学研究所 | Mlkl抑制剂 |
| US11666577B2 (en) * | 2017-02-28 | 2023-06-06 | National Institute Of Biological Sciences, Beijing | MLKL inhibitors |
| DK3652176T3 (da) * | 2017-07-11 | 2022-01-17 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
| CA3093084A1 (en) * | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| US12291532B2 (en) | 2018-12-12 | 2025-05-06 | Boehringer Ingelheim International Gmbh | Substituted xanthines as modulators of TRPC5 activity |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
| CN112979651B (zh) * | 2021-04-09 | 2022-02-01 | 南京纽邦生物科技有限公司 | 一种副黄嘌呤的制备方法 |
| CN113354646B (zh) * | 2021-07-06 | 2022-11-15 | 南开大学 | 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用 |
| CN115636831B (zh) * | 2022-10-27 | 2024-11-08 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
| WO2024133476A1 (en) | 2022-12-20 | 2024-06-27 | Boehringer Ingelheim International Gmbh | Process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| WO2024165540A1 (en) | 2023-02-06 | 2024-08-15 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione |
| WO2024164818A1 (zh) * | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
| WO2025250920A1 (en) | 2024-05-31 | 2025-12-04 | Gfb (Abc), Llc | Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| JP4191269B2 (ja) | 1996-05-17 | 2008-12-03 | 興和株式会社 | 新規なアニリド化合物及びこれを含有する医薬 |
| JPH10318487A (ja) | 1997-05-16 | 1998-12-04 | Mitsubishi Gas Chem Co Inc | 真空断熱材用ゲッタ |
| US6075029A (en) * | 1998-01-02 | 2000-06-13 | Cell Therapeutics, Inc. | Xanthine modulators of metabolism of cellular P-450 |
| US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
| CA2369981A1 (en) * | 1999-04-09 | 2000-10-19 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
| RU2003103103A (ru) * | 2000-07-04 | 2004-08-20 | Ново Нордиск А/С (DK) | Гетероциклические соединения, которые являются ингибиторами фермента dpp-iv |
| CN1486302A (zh) | 2000-12-07 | 2004-03-31 | CV���ƹ�˾ | 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶 |
| EP1368349B1 (de) * | 2001-02-24 | 2007-02-14 | Boehringer Ingelheim Pharma GmbH & Co.KG | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
| ATE520694T1 (de) * | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
| CA2524778C (en) * | 2003-05-06 | 2013-01-29 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| JP2007511528A (ja) | 2003-11-13 | 2007-05-10 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法 |
| EP1841448A2 (en) | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring beta-cell mass and function |
| US8143254B2 (en) | 2005-02-18 | 2012-03-27 | Cornell Research Foundation, Inc. | Methods for modulating ion channels |
| ES2401128T3 (es) * | 2005-08-10 | 2013-04-17 | Glaxosmithkline Llc | Derivados de xantina como agonistas selectivos de HM74A |
| US20080214563A1 (en) | 2005-09-06 | 2008-09-04 | Mui Cheung | Benzimidazole Thiophene Compounds As Plk Modulators |
| EP1963325A2 (en) * | 2005-12-07 | 2008-09-03 | UCB Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
| AU2006327181A1 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
| WO2007084728A2 (en) | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
| WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
| US20090269313A1 (en) | 2006-07-19 | 2009-10-29 | Diakine Therapeutics, Inc. | Encapsulation system |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| US20120148604A1 (en) | 2009-08-20 | 2012-06-14 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
| WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
| WO2012050641A2 (en) | 2010-06-08 | 2012-04-19 | Hydra Biosciences, Inc | Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents |
| JP2013023102A (ja) | 2011-07-22 | 2013-02-04 | Panasonic Corp | 列車情報提供システム |
| AR087501A1 (es) * | 2011-08-09 | 2014-03-26 | Hydra Biosciences Inc | Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 |
| CN103121970B (zh) | 2012-12-04 | 2015-04-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用 |
| CN107082782B (zh) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
-
2014
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-14 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en not_active Ceased
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active Active
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
-
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
- 2015-09-15 PH PH12015502141A patent/PH12015502141B1/en unknown
-
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
-
2017
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
-
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
-
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
-
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active
-
2024
- 2024-02-21 US US18/583,293 patent/US20250034143A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY189912A (en) | Substituted xanthines and methods of use thereof | |
| WO2014152287A3 (en) | Substituted xanthines and methods of use thereof | |
| MX2016004927A (es) | Composiciones utiles para tratar trastornos relacionados con kit. | |
| AU2019268062A1 (en) | Benzoquinolone inhibitors of VMAT2 | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| IN2015DN00127A (https=) | ||
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| IL241191B (en) | Local compositions and kits that include them for the treatment of local disorders | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| MY192489A (en) | Selectively substituted quinoline compounds | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| EP3008168A4 (en) | Sc- cells and compositions and methods for generating the same | |
| HK1217410A1 (zh) | Erk抑制劑及其用途 | |
| CA3284288A1 (en) | Topical compositions and methods of using the same | |
| EP3082819A4 (en) | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| IL244182B (en) | Preparations, methods and systems for the treatment of skin disorders | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| IN2013MU03641A (https=) | ||
| IN2014DN11078A (https=) | ||
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers |